Cargando…
β3 adrenergic receptor as potential therapeutic target in ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) disrupts renal parenchyma through progressive expansion of fluid‐filled cysts. The only approved pharmacotherapy for ADKPD involves the blockade of the vasopressin type 2 receptor (V2R). V2R is a GPCR expressed by a subset of renal tubular cells a...
Autores principales: | Schena, Giorgia, Carmosino, Monica, Chiurlia, Samantha, Onuchic, Laura, Mastropasqua, Mauro, Maiorano, Eugenio, Schena, Francesco P., Caplan, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531837/ https://www.ncbi.nlm.nih.gov/pubmed/34676684 http://dx.doi.org/10.14814/phy2.15058 |
Ejemplares similares
-
β(3) adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function
por: Procino, Giuseppe, et al.
Publicado: (2016) -
Everything You Always Wanted to Know about β(3)-AR * (* But Were Afraid to Ask)
por: Schena, Giorgia, et al.
Publicado: (2019) -
Dopamine receptor antagonists as potential therapeutic agents for ADPKD
por: Paul, Parama, et al.
Publicado: (2019) -
The expression of Lamin A mutant R321X leads to endoplasmic reticulum stress with aberrant Ca(2+) handling
por: Carmosino, Monica, et al.
Publicado: (2016) -
Serum Levels of miR-148b and Let-7b at Diagnosis May Have Important Impact in the Response to Treatment and Long-Term Outcome in IgA Nephropathy
por: Kouri, Nikoleta M., et al.
Publicado: (2021)